Cell Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Cell Biotech has a total shareholder equity of ₩117.2B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩123.2B and ₩6.0B respectively. Cell Biotech's EBIT is ₩8.1B making its interest coverage ratio -2.6. It has cash and short-term investments of ₩79.7B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -2.6x |
| Cash | ₩79.66b |
| Equity | ₩117.21b |
| Total liabilities | ₩5.99b |
| Total assets | ₩123.20b |
Recent financial health updates
No updates
Recent updates
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings
Aug 24
Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18Financial Position Analysis
Short Term Liabilities: A049960's short term assets (₩89.3B) exceed its short term liabilities (₩5.5B).
Long Term Liabilities: A049960's short term assets (₩89.3B) exceed its long term liabilities (₩520.1M).
Debt to Equity History and Analysis
Debt Level: A049960 is debt free.
Reducing Debt: A049960 has not had any debt for past 5 years.
Debt Coverage: A049960 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A049960 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 18:27 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cell Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young Ok Kim | DAOL Investment & Securities Co., Ltd. |
| Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |
| Tae Hyun Kim | IBK Securities Co. Ltd. |